Advancements in technologies for high-definition endoscopy, including fluorescent techniques, Raman spectrometry, and artificial intelligence [109–113], will hopefully provide increasing evidence that periodic endoscopic surveillance of pathogenic CDH1 variant carriers is an adequate preventive option for those at risk of GC. This evidence concerns the gene CDH1 and gastric cancer.